WAVE Life Sciences Ltd.
WVE
$8.75
$0.121.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -55.82% | -26.82% | 188.23% | -115.60% | -10.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -55.82% | -26.82% | 188.23% | -115.60% | -10.92% |
| Cost of Revenue | 7.62% | 21.45% | 31.02% | 30.20% | 21.25% |
| Gross Profit | -67.96% | -50.40% | 879.25% | -378.13% | -84.70% |
| SG&A Expenses | 25.83% | 35.49% | 18.09% | 14.58% | 16.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.38% | 25.50% | 27.32% | 25.62% | 19.99% |
| Operating Income | -50.75% | -44.54% | 222.94% | -1,538.23% | -49.09% |
| Income Before Tax | -53.29% | -48.55% | 279.95% | -1,039.62% | -56.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.29% | -48.55% | 279.95% | -951.90% | -56.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.29% | -48.55% | 279.95% | -951.90% | -56.00% |
| EBIT | -50.75% | -44.54% | 222.94% | -1,538.23% | -49.09% |
| EBITDA | -52.64% | -46.42% | 235.64% | -1,216.24% | -53.25% |
| EPS Basic | -21.09% | -18.15% | 222.12% | -806.06% | -27.04% |
| Normalized Basic EPS | -21.08% | -18.15% | 222.11% | -850.77% | -27.02% |
| EPS Diluted | -21.09% | -18.15% | 212.24% | -812.12% | -27.04% |
| Normalized Diluted EPS | -21.08% | -18.15% | 214.46% | -858.59% | -27.02% |
| Average Basic Shares Outstanding | 26.60% | 25.73% | 47.31% | 25.03% | 22.82% |
| Average Diluted Shares Outstanding | 26.60% | 25.73% | 57.16% | 23.92% | 22.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |